ArticleBiosafety and health2023
Risk and countermeasure of laboratory-acquired infection based on pathogen transmission routes.
Article in Biosafety and health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A review of post-exposure strategies for high-consequence viral pathogens in the laboratory.Clinical microbiology reviews · 2025Review
- Biosafety concept: Origins, Evolution, and Prospects.Biosafety and health · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Laboratory-acquired infection (LAI) is an important issue in laboratory biosafety for pathogenic microorganism, which aims to prevent the spread of infectious pathogens and protect laboratory personnel from potentially harmful microorganisms. Previous LAI reports provided a source of information for understanding the transmission routes and therapies helping to develop targeted prevention and response programs and to comprehensively ensure the biosafety of laboratories. In this study, from the perspective of the transmission routes of agents, the biosafety risks were discussed from four aspects: skin, eye, or mucous membrane exposure, contaminated sharp inoculation or bites from infected animals and arthropod vectors, ingestion or hand-to-mouth exposure, and inhalation of infectious aerosols. The development and evolution of LAI were reviewed, and appropriate countermeasures and suggestions were proposed accordingly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.